Paul M. Ridker

237.5k citations
815 papers · 130.9k indexed · 70 hit papers · h-index 173
Co-authors
Nader RifaiPeter LibbyJulie E. BuringNancy R. CookCharles H. HennekensRobert J. GlynnMeir J. StampferAttilio Maseri
Topics
Lipoproteins and Cardiovascular Health (287 papers)Adipokines, Inflammation, and Metabolic Diseases (214 papers)Diabetes, Cardiovascular Risks, and Lipoproteins (132 papers)
Cited by
Cardiology and Cardiovascular MedicineEndocrinology, Diabetes and MetabolismInternal Medicine
Journals
NatureNew England Journal of MedicineProceedings of the National Academy of Sciences
Partner nations
United StatesNetherlandsUnited Kingdom

In The Last Decade

Paul M. Ridker

807 papers receiving 126.2k citations

Hit Papers

Inflammation and Atherosclerosis1995202620052015200220081997200920112.0k4.0k6.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Inflammation and Atherosclerosis
    2002 6.0k citations Peter Libby, Paul M. Ridker et al. Circulation profile →
  2. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
    2008 4.7k citations Paul M. Ridker, Eleanor Danielson et al. profile →
  3. Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men
    1997 4.4k citations Paul M. Ridker et al. profile →
  4. Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
    2009 2.9k citations Paul M. Ridker, Eleanor Danielson et al. profile →
  5. Progress and challenges in translating the biology of atherosclerosis
    2011 2.9k citations Peter Libby, Paul M. Ridker et al. profile →
  6. Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
    2002 2.7k citations Paul M. Ridker, Nader Rifai et al. profile →
  7. Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and Prevention
    2003 2.0k citations Paul M. Ridker Circulation profile →
  8. Plasma Concentration of Interleukin-6 and the Risk of Future Myocardial Infarction Among Apparently Healthy Men
    2000 1.9k citations Paul M. Ridker, Nader Rifai et al. Circulation profile →
  9. C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events
    2003 1.8k citations Paul M. Ridker, Julie E. Buring et al. Circulation profile →
  10. Lack of Effect of Long-Term Supplementation with Beta Carotene on the Incidence of Malignant Neoplasms and Cardiovascular Disease
    1996 1.7k citations Bernard Rosner, Paul M. Ridker et al. profile →
  11. C-Reactive Protein Levels and Outcomes after Statin Therapy
    2005 1.7k citations Paul M. Ridker, Nader Rifai et al. profile →
  12. Inflammation in Atherosclerosis
    2009 1.6k citations Peter Libby, Paul M. Ridker et al. profile →
  13. A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
    2005 1.4k citations Paul M. Ridker, I‐Min Lee et al. profile →
  14. Prospective Study of C-Reactive Protein and the Risk of Future Cardiovascular Events Among Apparently Healthy Women
    1998 1.3k citations Paul M. Ridker, Julie E. Buring et al. Circulation profile →
  15. Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in Women
    2007 1.3k citations Paul M. Ridker, Julie E. Buring et al. profile →
  16. Effect of Statin Therapy on C-Reactive Protein Levels
    2001 1.3k citations Nader Rifai, Paul M. Ridker et al. profile →
  17. Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events
    2001 1.2k citations Paul M. Ridker, Nader Rifai et al. profile →
  18. Fasting Compared With Nonfasting Triglycerides and Risk of Cardiovascular Events in Women
    2007 1.2k citations Julie E. Buring, Nader Rifai et al. profile →
  19. Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein
    1999 1.2k citations Paul M. Ridker, Nader Rifai et al. Circulation profile →
  20. High-Sensitivity C-Reactive Protein
    2001 1.1k citations Paul M. Ridker Circulation profile →
  21. Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels
    1998 1.1k citations Paul M. Ridker, Nader Rifai et al. Circulation profile →
  22. Inflammation as a Cardiovascular Risk Factor
    2004 1.0k citations Paul M. Ridker et al. Circulation profile →
  23. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men
    1998 1.0k citations Paul M. Ridker et al. profile →
  24. Effect of sleep loss on C-Reactive protein, an inflammatory marker of cardiovascular risk
    2004 918 citations Paul M. Ridker, Nader Rifai et al. profile →
  25. Blood Levels of Long-Chain n–3 Fatty Acids and the Risk of Sudden Death
    2002 885 citations Paul M. Ridker et al. profile →
  26. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease
    2016 857 citations Daniel I. Chasman, Roxana Mehran et al. profile →
  27. Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer
    2005 842 citations I‐Min Lee, Paul M. Ridker et al. profile →
  28. Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy Men
    1995 826 citations Paul M. Ridker et al. profile →
  29. C-Reactive Protein Adds to the Predictive Value of Total and HDL Cholesterol in Determining Risk of First Myocardial Infarction
    1998 805 citations Paul M. Ridker, Robert J. Glynn et al. Circulation profile →
  30. Elevation of Tumor Necrosis Factor-α and Increased Risk of Recurrent Coronary Events After Myocardial Infarction
    2000 777 citations Paul M. Ridker, Nader Rifai et al. Circulation profile →
  31. Plasma Concentration of C-Reactive Protein and Risk of Developing Peripheral Vascular Disease
    1998 774 citations Paul M. Ridker et al. Circulation profile →
  32. Efficient Bayesian mixed-model analysis increases association power in large cohorts
    2015 766 citations Daniel I. Chasman, Paul M. Ridker et al. profile →
  33. Physical Activity and Reduced Risk of Cardiovascular Events
    2007 752 citations Samia Mora, Julie E. Buring et al. Circulation profile →
  34. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
    2009 751 citations Paul M. Ridker, Eleanor Danielson et al. profile →
  35. Prevention Conference V
    2000 742 citations Paul M. Ridker et al. Circulation profile →
  36. Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms
    2005 730 citations Paul M. Ridker et al. profile →
  37. From C-Reactive Protein to Interleukin-6 to Interleukin-1
    2016 693 citations Paul M. Ridker profile →
  38. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
    2001 638 citations Paul M. Ridker, Nader Rifai et al. profile →
  39. C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction
    2008 626 citations Paul M. Ridker, Nina P. Paynter et al. Circulation profile →
  40. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
    2011 609 citations Paul M. Ridker, Tom Thurén et al. profile →
  41. Low-Dose Aspirin in the Primary Prevention of Cancer
    2005 605 citations I‐Min Lee, Paul M. Ridker et al. profile →
  42. Novel Clinical Markers of Vascular Wall Inflammation
    2001 591 citations Paul M. Ridker et al. profile →
  43. Non–HDL Cholesterol, Apolipoproteins A-I and B100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women
    2005 585 citations Paul M. Ridker, Nader Rifai et al. profile →
  44. Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins
    2012 577 citations S. Matthijs Boekholdt, Samia Mora et al. profile →
  45. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial
    2012 562 citations Paul M. Ridker, Jean MacFadyen et al. profile →
  46. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials
    2009 561 citations Paul M. Ridker et al. profile →
  47. Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
    2003 551 citations Paul M. Ridker et al. profile →
  48. Clinical Efficacy of an Automated High-Sensitivity C-Reactive Protein Assay
    1999 550 citations Nader Rifai, Paul M. Ridker et al. profile →
  49. Blood Pressure and Inflammation in Apparently Healthy Men
    2001 547 citations Nader Rifai, Paul M. Ridker et al. Hypertension profile →
  50. Inflammatory Biomarkers, Hormone Replacement Therapy, and Incident Coronary Heart Disease
    2002 543 citations Nader Rifai, Paul M. Ridker et al. profile →
  51. A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism
    2009 543 citations Robert J. Glynn, Eleanor Danielson et al. profile →
  52. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure
    2019 458 citations Brendan M. Everett, Jan H. Cornel et al. Circulation profile →
  53. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials
    2015 455 citations Daniel I. Chasman, Paul M. Ridker et al. profile →
  54. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
    2021 433 citations Paul M. Ridker, G. Kees Hovingh et al. profile →
  55. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
    2021 406 citations Paul M. Ridker et al. profile →
  56. Inflammation, Immunity, and Infection in Atherothrombosis
    2018 401 citations Peter Libby, Joseph Loscalzo et al. profile →
  57. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
    2018 395 citations Paul M. Ridker, Peter Libby et al. European Heart Journal profile →
  58. Sugar-Sweetened Beverages and Genetic Risk of Obesity
    2012 380 citations Paul M. Ridker, Daniel I. Chasman et al. profile →
  59. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
    2018 365 citations Paul M. Ridker, Samia Mora et al. profile →
  60. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials
    2023 325 citations Paul M. Ridker, Deepak L. Bhatt et al. profile →
  61. A Multivariate Genome-Wide Association Analysis of 10 LDL Subfractions, and Their Response to Statin Treatment, in 1868 Caucasians
    2015 324 citations Daniel I. Chasman, Samia Mora et al. profile →
  62. Statins: new American guidelines for prevention of cardiovascular disease
    2013 322 citations Paul M. Ridker et al. profile →
  63. Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk
    2013 319 citations Brendan M. Everett, Paul M. Ridker et al. Circulation profile →
  64. A Test in Context
    2016 274 citations Paul M. Ridker profile →
  65. Targeting cardiovascular inflammation: next steps in clinical translation
    2020 269 citations Deepak L. Bhatt, Paul M. Ridker et al. European Heart Journal profile →
  66. TET2-Driven Clonal Hematopoiesis and Response to Canakinumab
    2022 218 citations E. C. Svensson, Aviv Madar et al. profile →
  67. Targeting innate immunity-driven inflammation in CKD and cardiovascular disease
    2022 135 citations Paul M. Ridker et al. profile →
  68. Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women
    2024 109 citations Paul M. Ridker, Nader Rifai et al. profile →
  69. Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease
    2023 101 citations Paul M. Ridker et al. profile →
  70. Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study
    2025 19 citations Jordan M Kraaijenhof, Nick S. Nurmohamed et al. European Heart Journal profile →

Peers

Paul M. Ridker
Comparison fields: 5 of 217
  • Surgery 41.7k
  • Cardiology and Cardiovascular Medicine 38.4k
  • Epidemiology 32.2k
  • Endocrinology, Diabetes and Metabolism 23.9k
  • Immunology 21.0k
Replace Peter Libby with:
Peter Libby United States
Nader Rifai United States
Russell P. Tracy United States
Meir J. Stampfer United States
Charles H. Hennekens United States
Peter W.F. Wilson United States
Valentı́n Fuster United States
Scott M. Grundy United States
Børge G. Nordestgaard Denmark
Jean‐Louis Vincent Belgium
Paul M. Ridker relative to Peter Libby United States Peter Libby's profile →
Citations per field
00.5×1.5×2.0×
Peter Libby · 1×
Citations per year

Countries citing papers authored by Paul M. Ridker

Since Specialization
Citations

This map shows the geographic impact of Paul M. Ridker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul M. Ridker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul M. Ridker more than expected).

Fields of papers citing papers by Paul M. Ridker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul M. Ridker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul M. Ridker. The network helps show where Paul M. Ridker may publish in the future.

Co-authorship network of co-authors of Paul M. Ridker

This figure shows the co-authorship network connecting the top 25 collaborators of Paul M. Ridker. A scholar is included among the top collaborators of Paul M. Ridker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul M. Ridker. Paul M. Ridker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1
Effect of intravenous methotrexate carried by lipid nanoemulsion in patients with anterior ST-elevation myocardial infarction
2025 ·IJC Heart & Vasculature ·(unknown),Raul Cavalcante Maranhão,Rocío Salsoso,(unknown),Remo H.M. Furtado,Talia Falcão Dalçóquio,Carlos Alberto Kenji Nakashima,Luciano Baracioli,Felipe Gallego Lima,(unknown),(unknown),Carlos Eduardo Rochitte,César Higa Nomura,Roberto Kalil Filho,Paul M. Ridker,Robert P. Giugliano,Marc S. Sabatine,(unknown),Roberto R. Giraldez,José Carlos Nicolau
0
2
Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk studybreakdown →
2025 ·European Heart Journal ·Jordan M Kraaijenhof,Nick S. Nurmohamed,Ask Tybjærg Nordestgaard,Laurens F. Reeskamp,(unknown),G. Kees Hovingh,S. Matthijs Boekholdt,Paul M. Ridker
19
3
Low-dose colchicine for atherosclerosis: long-term safety
2024 ·European Heart Journal ·Stefan M. Nidorf,Eldad Ben‐Chetrit,Paul M. Ridker
33
4
Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial
2023 ·Blood Advances ·Janghee Woo,Darlene Lu,Andrew Lewandowski,Huilei Xu,Pablo Serrano Balazote,Margaret L. Healey,Denise P. Yates,Michael T. Beste,Peter Libby,Paul M. Ridker,David P. Steensma
23
5
Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction
2023 ·European Heart Journal - Cardiovascular Pharmacotherapy ·Serge Korjian,(unknown),Gerald Chi,Arzu Kalaycı,Jane Lee,(unknown),Samuel D. Wright,Danielle Duffy,Bronwyn A. Kingwell,Roxana Mehran,Paul M. Ridker,C. Michael Gibson
15
6
Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance
2023 ·Circulation ·Paul M. Ridker,Lei Lei,Michael J. Louie,Tariq Haddad,Stephen J. Nicholls,A. Michael Lincoff,Peter Libby,Steven E. Nissen,(unknown)
62
7
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy
2022 ·Circulation ·Paul M. Ridker,Nader Rifai,Jean MacFadyen,Robert J. Glynn,Lixia Jiao,Philippe Gabríel Steg,Michael Miller,Eliot A. Brinton,Terry A. Jacobson,Jean‐Claude Tardif,Christie M. Ballantyne,R. Preston Mason,Deepak L. Bhatt
80
8
Association Between Hemostatic Profile and Migraine
2021 ·Neurology ·Yanjun Guo,Pamela M. Rist,Maria Sabater‐Lleal,Paul S. de Vries,Nicholas L. Smith,Paul M. Ridker,Tobias Kurth,Daniel I. Chasman
11
9
Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial
2020 ·Cancer Research ·Connie Wong,Jason Baum,(unknown),Michael T. Beste,(unknown),Siyan Xu,Ying A. Wang,Tony Wang,Margaret F. Prescott,(unknown),Margaret Dugan,Paul M. Ridker,Anne‐Marie Martin,E. C. Svensson
63
10
COVID-19 – A vascular disease
2020 ·Trends in Cardiovascular Medicine ·Hasan K. Siddiqi,Peter Libby,Paul M. Ridker
229
11
Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failurebreakdown →
2019 ·Circulation ·Brendan M. Everett,Jan H. Cornel,Mitja Lainščak,Stefan D. Anker,Antonio Abbate,Tom Thurén,Peter Libby,Robert J. Glynn,Paul M. Ridker
458
12
Gene-Based Elevated Triglycerides and Type 2 Diabetes Mellitus Risk in the Women’s Genome Health Study
2018 ·Arteriosclerosis Thrombosis and Vascular Biology ·Shafqat Ahmad,Samia Mora,Paul M. Ridker,Frank B. Hu,Daniel I. Chasman
14
13
Abstract 15111: TET2-Driven Clonal Hematopoiesis Predicts Enhanced Response to Canakinumab in the CANTOS Trial: An Exploratory Analysis
2018 ·Circulation ·E. C. Svensson,Aviv Madar,Catarina D. Campbell,Yunsheng He,Marc Sultan,Margaret L. Healey,(unknown),Anita Fernandez,(unknown),Paul M. Ridker,Michael T. Beste,Craig T. Basson
32
14
Primary Prevention With Statin Therapy in the Elderly
2017 ·Circulation ·Paul M. Ridker,Eva Lonn,Nina P. Paynter,Robert J. Glynn,Salim Yusuf
89
15
Plasma C-Reactive Protein and Risk of Breast Cancer in Two Prospective Studies and a Meta-analysis
2015 ·Cancer Epidemiology Biomarkers & Prevention ·Jun Wang,I‐Min Lee,Shelley S. Tworoger,Julie E. Buring,Paul M. Ridker,Bernard Rosner,Susan E. Hankinson
43
16
Catechol-O-methyltransferase Associated Risk of Cardiovascular Disease Is Modified by Treatment with Vitamin E
2014 ·The Journal of Alternative and Complementary Medicine ·Kathryn Hall,Christopher P. Nelson,Roger B. Davis,Julie E. Buring,Irving Kirsch,Murray A. Mittleman,Joseph Loscalzo,Nilesh J. Samani,Paul M. Ridker,Ted J. Kaptchuk,Daniel I. Chasman
1
17
Effects of Interleukin-1β Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen
2012 ·Circulation ·Paul M. Ridker,Campbell P. Howard,Verena Walter,Giulia Renda,Peter Libby,Johannes Hensen,Tom Thurén
430
18
C-reactive Protein and Risk of Colorectal Adenoma According to Celecoxib Treatment
2011 ·Cancer Prevention Research ·Andrew T. Chan,Camelia S. Sima,Ann G. Zauber,Paul M. Ridker,Ernest T. Hawk,Monica M. Bertagnolli
18
19
Abstract 3135: Association of 77 Polymorphisms in 52 Candidate Genes with Blood Pressure Progression and Incident Hypertension: The Women's Genome Health Study
2008 ·Circulation ·David Conen,Suzanne Cheng,Lori Steiner,Julie E. Buring,Paul M. Ridker,Robert Y.L. Zee
1
20
Valsartan, Blood Pressure Reduction, and C-Reactive Protein
2006 ·Hypertension ·Paul M. Ridker,Eleanor Danielson,Nader Rifai,Robert J. Glynn
119

About Paul M. Ridker

Paul M. Ridker is a scholar working on Endocrinology, Diabetes and Metabolism, Internal Medicine and Cardiology and Cardiovascular Medicine, having authored 815 papers that have together received 130.9k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (287 papers), Adipokines, Inflammation, and Metabolic Diseases (214 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (132 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (38.4k citations), Endocrinology, Diabetes and Metabolism (23.9k citations) and Internal Medicine (4.7k citations). Paul M. Ridker has collaborated with scholars based in United States, Netherlands and United Kingdom. Frequent co-authors include Nader Rifai, Peter Libby, Julie E. Buring, Nancy R. Cook, Charles H. Hennekens, Robert J. Glynn, Meir J. Stampfer, Attilio Maseri, JoAnn E. Manson and Samia Mora. Their work appears in journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter LibbyBreakdown of academic impact, for papers by Nader RifaiBreakdown of academic impact, for papers by Russell P. TracyBreakdown of academic impact, for papers by Meir J. StampferBreakdown of academic impact, for papers by Charles H. HennekensBreakdown of academic impact, for papers by Peter W.F. WilsonBreakdown of academic impact, for papers by Valentı́n FusterBreakdown of academic impact, for papers by Scott M. GrundyBreakdown of academic impact, for papers by Børge G. NordestgaardBreakdown of academic impact, for papers by Jean‐Louis Vincent
Rankless by CCL
2026